Critical Survey: iBio (NYSE:IBIO) vs. Vincerx Pharma (NASDAQ:VINC)

Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Vincerx Pharma and iBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
iBio	N/A	-73.15%	-45.51%

Insider & Institutional Ownership

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Vincerx Pharma and iBio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00
iBio	$500,000.00	99.39	-$24.91 million	($1.39)	-1.59

iBio has higher revenue and earnings than Vincerx Pharma. iBio is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vincerx Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, iBio has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Vincerx Pharma and iBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vincerx Pharma	0	0	0	0	0.00
iBio	0	0	3	0	3.00

iBio has a consensus target price of $4.00, indicating a potential upside of 81.00%. Given iBio’s stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Vincerx Pharma.

Summary

iBio beats Vincerx Pharma on 8 of the 12 factors compared between the two stocks.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.